Dataset from A Phase IIb, Randomized (Stratified), Double-Blind (Sponsor Open), Parallel-Group, Placebo-Controlled, Dose-Finding Study of Nemiralisib (GSK2269557) Added to Standard of Care (SoC) Versus SoC Alone in Participants Diagnosed With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

Nemiralisib is being developed as an anti-inflammatory drug for the treatment of inflammatory
airways disease. This study is designed to assess the dose response, efficacy, safety, and
pharmacokinetics of nemiralisib across a range of doses [up to 750 micrograms (µg)] compared
with placebo. The study consists of a Screening Period, a 12-Week Treatment Period and a
12-Week Post-Treatment Follow-Up Period. Approximately 1,250 subjects with an acute moderate
or severe exacerbation of COPD requiring standard of care (SoC) therapy will be randomized in
this double-blind study. Subjects will be randomized to receive different doses of
nemiralisib or placebo via ELLIPTA® inhaler. The total duration of study participation is
approximately 6 months (170 days). ELLIPTA is the registered trademark of GlaxoSmithKline
(GSK) group of companies.